Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to improve outcomes.
Vous n'êtes pas connecté
In patients hospitalized for medlinkacute myocardial infarction/medlink (MI), the SGLT2 inhibitor empagliflozin offers significant kidney protection.
Empagliflozin, an SGLT2 inhibitor, is proven safe and effective for heart attack patients, offering a new treatment option to improve outcomes.
MONDAY, Sept. 9, 2024 -- Empagliflozin confers kidney-protective benefits for patients with acute myocardial infarction (MI) and an increased risk...
WEDNESDAY, Sept 4, 2024 -- Young patients with myocardial infarction (MI) and fewer traditional risk factors often have greater exposure to urban...
Atrial fibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought,...
A Perth professor who has significantly changed the treatment of cancer patients worldwide will trial his method on patients who are suffering from...
A Perth professor who has significantly changed the treatment of cancer patients worldwide will trial his method on patients who are suffering from...
Boris Shcherbakov’s wife, actress Tatyana Bronzova, said in her speech: TASSShe said her husband had been discharged from the hospital. Bronzova...
Boris Shcherbakov’s wife, actress Tatyana Bronzova, said in her speech: TASSShe said her husband had been discharged from the hospital. Bronzova...
Saint Paul General Hospital held a farewell ceremony for the first two patients who received kidney transplants from a brain-dead donor.
Saint Paul General Hospital held a farewell ceremony for the first two patients who received kidney transplants from a brain-dead donor.